Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 199 results for biopsy

  1. Low dose rate brachytherapy for localised prostate cancer (HTG81)

    Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.

    HealthTech guidance
    Published
    27 July 2005
    View recommendations

    Sections for HTG81

  2. Endoscopic axillary lymph node retrieval for breast cancer (HTG93)

    Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.

    HealthTech guidance
    Published
    14 December 2005
    View recommendations

    Sections for HTG93

  3. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

    NICE guideline
    Last updated
    14 April 2025
    View recommendations

    Sections for NG101

  4. Photodynamic therapy for early-stage oesophageal cancer (HTG128)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

    HealthTech guidance
    Published
    13 December 2006
    View recommendations

    Sections for HTG128

  5. ADXBLADDER for detecting bladder cancer (MIB180)

    NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .

    Medtech innovation briefing
    Published
    12 April 2019

  6. Non-invasive tests for diagnosing NAFLD in adults:- Which non-invasive tests are most accurate and cost-effective in identifying non-alcoholic fatty liver disease (NAFLD) in adults with risk factors, type 2 diabetes and metabolic syndrome?

    at risk.The 'gold standard' for diagnosis is liver biopsy. It is not feasible to perform liver biopsy in large numbers of...

    Research recommendation
    Published
    24 August 2016

  7. Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions (HTG232)

    Evidence-based recommendations on endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) of non-ampullary duodenal lesions. This involves using a long camera inserted through the mouth to view the area and removing the abnormal parts of the lining with special instruments.

    HealthTech guidance
    Published
    27 October 2010
    View recommendations

    Sections for HTG232

  8. Skin cancer (QS130)

    This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    24 January 2024
    View quality statements

    Sections for QS130

  9. MMprofiler for prognostic risk classification in multiple myeloma (MIB270)

    NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .

    Medtech innovation briefing
    Published
    10 August 2021

  10. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (HTG333)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

    HealthTech guidance
    Published
    26 February 2014
    View recommendations

    Sections for HTG333

  11. Telbivudine for the treatment of chronic hepatitis B (TA154)

    Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    27 August 2008
    View recommendations

    Sections for TA154

  12. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

    HealthTech guidance
    Published
    29 August 2012
    View recommendations

    Sections for HTG291

  13. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)

    Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.

    Technology appraisal guidance
    Published
    19 February 2025
    View recommendations

    Sections for TA1042

  14. In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most accurate tests for diagnosing the infection and when should they be done?

    endotracheal aspirate, sputum samples, serum assays) Reference standard:• lung biopsy or postmortem diagnosis Target condition:• CAPA...

    Research recommendation
    Published
    17 December 2021

  15. Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)

    Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making

    Medtech innovation briefing
    Published
    28 June 2016